Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Ibuprofen (MOMENT ACT ANALGESIC Granules) Pharmacokinetic Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02482155
Recruitment Status : Completed
First Posted : June 26, 2015
Last Update Posted : June 26, 2015
Sponsor:
Collaborator:
Cross Research S.A.
Information provided by (Responsible Party):
Aziende Chimiche Riunite Angelini Francesco S.p.A

Brief Summary:
The main purpose of this study was to evaluate the pharmacokinetic (PK) profile of ibuprofen after oral administration of a single dose of MOMENT ACT ANALGESIC granules to healthy male and female subjects, under fasting conditions.

Condition or disease Intervention/treatment Phase
Healthy Drug: Ibuprofen Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 24 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Official Title: Pharmacokinetic Study of a Single Oral Administration of MOMENT ACT ANALGESIC Granules for Oral Solution to Healthy Volunteers Under Fasting Conditions Single Centre, Single Dose, Open-label, Bioavailability Study
Study Start Date : February 2015
Actual Primary Completion Date : March 2015
Actual Study Completion Date : March 2015

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: ibuprofen
ibuprofen 400 mg granules, oral solution, single administration under fasting conditions
Drug: Ibuprofen
ibuprofen 400 mg single dose oral solution
Other Name: MOMENTACT




Primary Outcome Measures :
  1. Maximum plasma concentration (Cmax) of ibuprofen [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  2. Area under the plasma concentration versus time curve (AUC) of ibuprofen [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  3. Time to Cmax (Tmax) of ibuprofen [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  4. Apparent terminal elimination rate constant (λz) of ibuprofen [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  5. Apparent terminal elimination half-life (t1/2,z) of ibuprofen [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  6. Lag-time from the dosing time point prior to the first measurable plasma concentration (tlag) of ibuprofen [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  7. Time to the first ibuprofen plasma concentration of 5 ug/mL (ton5) [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]

Secondary Outcome Measures :
  1. Time to the first ibuprofen plasma concentration of 10 ug/mL (ton10) [ Time Frame: 0, 3, 5, 10, 15, 20, 30, 45 minutes, 1, 1.5, 2, 3, 4, 6, 9, 12, 16, 24 hours post-dose ]
  2. Occurrence of adverse effects [ Time Frame: up to 24 hours after administration ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Informed consent: signed written informed consent before inclusion in the study;
  2. Sex and age: females and males, 18-55 years old both inclusive;
  3. Body Mass Index (BMI): 18.5-30 kg/m2 inclusive;
  4. Vital signs: systolic blood pressure (SBP) 100-139 mmHg, diastolic blood pressure (DBP) 50-89 mmHg, heart rate (HR) 50-90 bpm, measured after 5 min at rest in the sitting position;
  5. Full comprehension: ability to comprehend the full nature and purpose of the study, including possible risks and side effects; ability to co-operate with the investigator and to comply with the requirements of the entire study;
  6. Contraception and fertility (females only): females of child-bearing potential must be using at least one of the following reliable methods of contraception:

    1. hormonal oral, implantable, transdermal, or injectable contraceptives for at least 2 months before the screening visit;
    2. a non-hormonal intrauterine device or female condom with spermicide or contraceptive sponge with spermicide or diaphragm with spermicide or cervical cap with spermicide for at least 2 months before the screening visit;
    3. a male sexual partner who agrees to use a male condom with spermicide;
    4. a sterile sexual partner. Female participants of non-child-bearing potential or in post-menopausal status for at least 1 year will be admitted. For all female subjects, pregnancy test result must be negative at screening and day -1.

Exclusion Criteria:

  1. Electrocardiogram (ECG) 12-leads (supine position): clinically significant abnormalities;
  2. Physical findings: clinically significant abnormal physical findings which could interfere with the objectives of the study;
  3. Laboratory analyses: clinically significant abnormal laboratory values indicative of physical illness;
  4. Allergy: ascertained or presumptive hypersensitivity to the active principle and/or formulations' ingredients or related drugs, namely non-steroidal anti-inflammatory agents (NSAIDs); history of anaphylaxis to drugs or allergic reactions in general, which the investigator considers may affect the outcome of the study;
  5. Diseases: history of significant renal, hepatic, gastrointestinal (in particular gastroduodenal ulcer and bleeding), cardiovascular, respiratory (in particular asthma), skin, haematological, endocrine or neurological diseases that may interfere with the aim of the study;
  6. Medications: medications, including over the counter (OTC) medications and herbal products for 2 weeks before the start of the study, in particular ibuprofen. Hormonal contraceptives for females are allowed;
  7. Investigative drug studies: participation in the evaluation of any investigational product in the 3 months before this study, calculated from the first day of the month following the last visit of the previous study;
  8. Blood donation: blood donations in the 3 months before this study;
  9. Drug, alcohol, caffeine, tobacco: history of drug, alcohol [>1 drink/day for females and >2 drinks/day for males, defined according to United States Department of Agriculture Dietary Guidelines 2010], caffeine (>5 cups coffee/tea/day) or tobacco abuse (>=10 cigarettes/day); daily use of distilled spirits;
  10. Drug test: positive result at the drug test at screening or day-1;
  11. Alcohol test: positive alcohol breath test at day -1;
  12. Diet: abnormal diets (<1600 or >3500 kcal/day) or substantial changes in eating habits in the 4 weeks before this study, vegetarians;
  13. Pregnancy (females only): positive or missing pregnancy test at screening or day -1, pregnant or lactating women.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02482155


Locations
Layout table for location information
Switzerland
CROSS Research S.A., Phase I Unit, Via F.A. Giorgioli 14 Phone: Fax: +41.91.63.00.511 Email:
Arzo, Switzerland, CH-6864
Sponsors and Collaborators
Aziende Chimiche Riunite Angelini Francesco S.p.A
Cross Research S.A.
Investigators
Layout table for investigator information
Principal Investigator: Milko Radicioni, MD Cross Research S.A.

Layout table for additonal information
Responsible Party: Aziende Chimiche Riunite Angelini Francesco S.p.A
ClinicalTrials.gov Identifier: NCT02482155     History of Changes
Other Study ID Numbers: 070(I)HO14386
CRO-PK-14-291 ( Other Identifier: CROSS Research S.A., Phase I Unit )
First Posted: June 26, 2015    Key Record Dates
Last Update Posted: June 26, 2015
Last Verified: June 2015
Keywords provided by Aziende Chimiche Riunite Angelini Francesco S.p.A:
pharmacokinetics
MOMENTACT
ibuprofen 400 mg
oral
granules
Additional relevant MeSH terms:
Layout table for MeSH terms
Ibuprofen
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Inflammatory Agents, Non-Steroidal
Analgesics, Non-Narcotic
Anti-Inflammatory Agents
Antirheumatic Agents
Cyclooxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action